Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

被引:106
作者
Hughes, A
Calvert, P
Azzabi, A
Plummer, R
Johnson, R
Rusthoven, J
Griffin, M
Fishwick, K
Boddy, AV
Verrill, M
Calvert, H
机构
[1] Newcastle Gen Hosp, Dept Med Oncol, No Ctr Canc Treatment, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[2] Newcastle Univ, Canc Res Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN USA
关键词
D O I
10.1200/JCO.2002.10.073
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended dose for phase II studies, and to explore its efficacy. We assessed toxicities and explored the activity of the drug combination exclusively in patients with malignant pleural mesothelioma (MPM). The pharmacokinetics of both agents was investigated. Patients and Methods: Twenty-seven patients (23 male, four female) with MPM were treated: on five escalating dose levels. Doses ranged from pemetrexed 400 mg/m(2) (as a 10-minute intravenous infusion), followed by carboplatin area under the plasma concentration-time curve (AUC) 4 mg/mL(.)min (as a 30-minute intravenous infusion) to pemetrexed 500 mg/m(2), Carboplatin AUC 6 mg/mL.min. All patients had a World Health Organization performance status of 1. A total of 163 courses of treatment were administered (median, six; range, one to 10). Results: The main toxicity was hematologic, particularly neutropenia, although this was characteristically short-lived and caused few clinical problems. The MTD was pemetrexed 500 mg/m(2), carboplatin AUC 6, because three of the five patients treated at this dose level experienced a dose-limiting toxicity. Eight partial responses (in 25 assessable patients) were observed for a response rate of 32%. Seventy percent of patients noticed an improvement in symptoms, usually (84%) after only two courses. Median time to progression was 305 days, and median survival time was 451 days. Conclusion: The MTD was pemetrexed 500 mg/m(2) and carboplatin AUC 6 mg/mL.min. The recommended phase II dose of the combination is pemetrexed 500 mg/m(2) and carboplatin AUC 5 mg/mL.min. The combination is both active and well tolerated in MPM and deserves further exploration. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:3533 / 3544
页数:12
相关论文
共 61 条
[1]  
AISNER J, 1995, CHEST, V108, P1122
[2]   MALIGNANT MESOTHELIOMA - PROGNOSTIC VARIABLES IN A REGISTRY OF 180 PATIENTS, THE DANA-FARBER-CANCER-INSTITUTE AND BRIGHAM-AND-WOMENS-HOSPITAL EXPERIENCE OVER 2 DECADES, 1965-1985 [J].
ANTMAN, K ;
SHEMIN, R ;
RYAN, L ;
KLEGAR, K ;
OSTEEN, R ;
HERMAN, T ;
LEDERMAN, G ;
CORSON, J .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (01) :147-153
[3]  
AVERSA SML, 1998, P EUR SOC MED ONCOL, V23, P72
[4]  
BELANI CP, 1999, P AN M AM SOC CLIN, V18, pA474
[5]  
Bischoff HG, 1998, P AM SOC CLIN ONCOL, V17, pA464
[6]  
Boddy AV, 2001, CANCER CHEMOTH PHARM, V48, P15
[7]   COMBINATION CHEMOTHERAPY VERSUS SINGLE AGENTS FOLLOWED BY COMBINATION CHEMOTHERAPY IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - A STUDY OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].
BONOMI, PD ;
FINKELSTEIN, DM ;
RUCKDESCHEL, JC ;
BLUM, RH ;
GREEN, MD ;
MASON, B ;
HAHN, R ;
TORMEY, DC ;
HARRIS, J ;
COMIS, R ;
GLICK, J .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1602-1613
[8]   Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay [J].
Britten, CD ;
Izbicka, E ;
Hilsenbeck, S ;
Lawrence, R ;
Davidson, K ;
Cerna, C ;
Gomez, L ;
Rowinsky, EK ;
Weitman, S ;
Von Hoff, DD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (02) :105-110
[9]   The α folate receptor is highly activated in malignant pleural mesothelioma [J].
Bueno, R ;
Appasani, K ;
Mercer, H ;
Lester, S ;
Sugarbaker, D .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (02) :225-233
[10]  
BUNN P, 2001, P AN M AM SOC CLIN, V20, pA76